Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum.
Prenatal screening for Down's syndrome (DS) is in need of improvement. As a powerful platform, proteomics techniques could also be used for identification of new biomarkers for DS screening. In this case-control proteome study, pregnant women were diagnosed prenatally by karyotype analysis from amniotic fluid (AF). Maternal serum samples were collected from six pregnancies with fetuses affected by DS and six pregnancies with normal fetuses. First, we used two-dimensional electrophoresis and mass spectrometry to identify the different levels of expression of proteins in maternal serum between the DS and control groups in the second trimester. Second, we used bioinformatics to analyze the proteins by DAVID. Then, the interesting candidates were further tested by enzyme-linked immunosorbent assay (ELISA). Twenty-nine proteins were successfully identified in maternal serum obtained from pregnancies with fetuses affected by DS. The top five proteins up-regulated were serotransferrin (TF), alpha-1b-glycoprotein (A1BG), desmin (DES), alpha-1-antitrypsin (SERPINA1) and ceruloplasmin (CP), while serum amyloid P-component (APCS) was the most down-regulated protein. These 29 proteins were categorized based on binding, catalytic activity and enzyme regulator activity. The biological roles were involved in biological regulation, metabolic processes, cellular processes and response to a stimulus. Based on ELISA, the median concentrations of CP and complement factor B (CFB) were 332.3 and 412.3 ng/mL, respectively. The concentrations of CP and CFB were significantly higher in the DS group than in the control group (P < 0.05). In conclusion, proteomic approaches offer the possibility of further improving the performance of DS screening and our identification of up- and down-regulated proteins may lead to new candidates for DS screening.
Department of Microbiology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212013, China.
Bin
B
Yu
Bin
B
Zhang
Jing
J
Wang
Qiu-wei
QW
Wang
Rui-ping
RP
Huang
Yu-qi
YQ
Yang
Shi-he
SH
Shao
D000328:Adult; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D002570:Ceruloplasmin / Q000032:analysis; D003893:Desmin / Q000097:blood; D004314:Down Syndrome / Q000097:blood* / Q000175:diagnosis*; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D011247:Pregnancy; D011262:Pregnancy Trimester, Second / Q000097:blood; D011296:Prenatal Diagnosis / Q000379:methods*; D040901:Proteomics / Q000379:methods; D000683:Serum Amyloid P-Component / Q000032:analysis; D014168:Transferrin / Q000032:analysis; D055815:Young Adult; D000515:alpha 1-Antitrypsin / Q000097:blood
C048566:A1BG protein, human; D015415:Biomarkers; D003893:Desmin; D006023:Glycoproteins; D007136:Immunoglobulins; C043392:SERPINA1 protein, human; D000683:Serum Amyloid P-Component; D014168:Transferrin; D000515:alpha 1-Antitrypsin; D002570:Ceruloplasmin